Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Inflarx (Germany)
h-index: 16
Total citations: 1,287
Total papers: 37
Homepage:
http://www.inflarx.com/
Recent papers from Inflarx (Germany)
A First‐In‐Human, Randomized, Placebo‐Controlled Single and Multiple Ascending Dose Study of Izicopan (INF904), A Second‐Generation Oral Small Molecule C5a Receptor Inhibitor, in Healthy Participants
Clinical Pharmacology in Drug Development · 2026
Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial
British Journal of Dermatology · 2025
A Targeted Blockade of Terminal C5a Is Critical to Management of Sepsis and Acute Respiratory Distress Syndrome: The Mechanism of Action of Vilobelimab
International Journal of Molecular Sciences · 2025
The Procaine-Based ProcCluster® Impedes the Second Envelopment Process of Herpes Simplex Virus Type 1
International Journal of Molecular Sciences · 2025
Toxicity study of TEoS-DAZA, a chemical precursor for functional liver imaging with PET/CT
EJNMMI Radiopharmacy and Chemistry · 2025
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients
BMJ Open Respiratory Research · 2025
Treatment of Pyoderma Gangrenosum With Vilobelimab
JAMA Dermatology · 2024
Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial
Critical Care · 2024
Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients
Intensive Care Medicine Experimental · 2023
Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial
Respiratory Research · 2022
The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19
Clinical and Translational Science · 2022
Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study)
Critical Care Explorations · 2021
Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4 -transgenic mice infected with MERS-CoV
Emerging Microbes & Infections · 2018
Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?
British Journal of Dermatology · 2018
The role of C5a in acute lung injury induced by highly pathogenic viral infections
Emerging Microbes & Infections · 2015
A Second Stimulus Required for Enhanced Antifungal Activity of Human Neutrophils in Blood Is Provided by Anaphylatoxin C5a
The Journal of Immunology · 2014
Treatment With Anti-C5a Antibody Improves the Outcome of H7N9 Virus Infection in African Green Monkeys
Clinical Infectious Diseases · 2014
Early Intra-Articular Complement Activation in Ankle Fractures
BioMed Research International · 2014
Inhibition of Complement Activation Alleviates Acute Lung Injury Induced by Highly Pathogenic Avian Influenza H5N1 Virus Infection
American Journal of Respiratory Cell and Molecular Biology · 2013
Opposite Role of Tumor Necrosis Factor Receptors in Dextran Sulfate Sodium-Induced Colitis in Mice
PLoS ONE · 2012